NYXH Nyxoah

Publication relating to transparency notifications

Publication relating to transparency notifications

                

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), November 18, 2024, 10:30 pm CET / 4:30 pm ET In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

On November 15, 2024, Nyxoah received a transparency notification from ResMed Inc. following the passive crossing of a threshold. Based on the notification, ResMed Inc. holds 1,727,864 voting rights, representing 4.62% of the total number of voting rights on October 9, 2024 (37,389,015).

The notification dated November 5, 2024 contains the following information:

  • Reason for the notification: passive crossing of a threshold
  • Notification by: a person that notifies alone
  • Persons subject to the notification requirement:
    • ResMed Inc. (with address at 9001 Spectrum Center Boulevard, San Diego, CA 92123, USA)
  • Date on which the threshold was crossed: October 9, 2024
  • Threshold that is crossed: 5%
  • Denominator: 37,389,015
  • Notified details:
A) Voting rights Previous notification After the transaction


 
# of voting rights # of voting rights % of voting rights
Holders of voting rights

 
Linked to securities Not linked to the securities Linked to securities Not linked to the securities
ResMed Inc. 1,619,756 1,727,864

 


 


 


 
TOTAL 1,727,864 0 4.62% 0.00%
  • Full chain of controlled undertakings through which the holding is effectively held: No indirect holding of voting securities. ResMed Inc. is not a controlled entity.



*

* *

Contact:

Nyxoah

John Landry, CFO

Attachment



EN
18/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Nyxoah Reports Second Quarter Financial and Operating Results

Nyxoah Reports Second Quarter Financial and Operating Results REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent F...

 PRESS RELEASE

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Sec...

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025 INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025La FDA approuve le système Genio® pour le marché américain ; la Société lance la commercialisation du produit Mont-Saint-Guibert, Belgique – 18 août 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) ...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates.  Preliminary, Unaudited Second Quarter 2025 Financial Results and Business U...

 PRESS RELEASE

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre ...

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025  Mont-Saint-Guibert, Belgique – 11 août 2025, 7h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui certains résultats financiers préliminaires non audités pour le deuxième trimestre 2025 et d'autres informations su...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch